(Q40144737)

English

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity

scientific article published on 29 January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity (English)

1 reference

Europe PubMed Central

17 September 2017

0 references

multiple sclerosis

0 references

author name string

Sominanda A

1

1 reference

Europe PubMed Central

17 September 2017

Rot U

2

1 reference

Europe PubMed Central

17 September 2017

Suoniemi M

3

1 reference

Europe PubMed Central

17 September 2017

Deisenhammer F

4

1 reference

Europe PubMed Central

17 September 2017

Hillert J

5

1 reference

Europe PubMed Central

17 September 2017

Fogdell-Hahn A

6

1 reference

Europe PubMed Central

17 September 2017

publication date

29 January 2007

1 reference

Europe PubMed Central

17 September 2017

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

17 September 2017

13

1 reference

Europe PubMed Central

17 September 2017

2

1 reference

Europe PubMed Central

17 September 2017

208-214

1 reference

Europe PubMed Central

17 September 2017

Immunogenicity of recombinant human proteins: causes and consequences

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070762

21 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070762

21 January 2018

Bioequivalence and the immunogenicity of biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070762

21 January 2018

The immunogenicity of biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070762

21 January 2018

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070762

21 January 2018

Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070762

21 January 2018

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070762

21 January 2018

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070762

21 January 2018

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070762

21 January 2018

T cell-independent antigens type 2.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070762

21 January 2018

Immunoglobulin Subclasses in Patients with Neutralizing and Nonneutralizing Antibodies Against IFN-β1b

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070762

21 January 2018

Identifiers

10.1177/1352458506070762

1 reference

Europe PubMed Central

17 September 2017

1 reference

Europe PubMed Central

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40144737&oldid=1886805086"